121 related articles for article (PubMed ID: 22902911)
1. The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?
Lin GW; Yao XD; Ye DW; Zhu Y; Zhang SL; Dai B; Zhang HL; Shen YJ; Ma CG
Asian J Androl; 2012 Sep; 14(5):732-7. PubMed ID: 22902911
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
[TBL] [Abstract][Full Text] [Related]
3. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Keizman D; Huang P; Carducci MA; Eisenberger MA
Prostate; 2012 Mar; 72(4):461-7. PubMed ID: 21688281
[TBL] [Abstract][Full Text] [Related]
4. Commentary on "Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel." Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A, Leibowitz-Amit R, Berger R, Keizman D, Department of Oncology, Rambam Medical Center, Haifa, Israel.: Prostate 2014 Apr;74(4):433-40; doi:10.1002/pros.22765. [Epub 2013 Dec 11].
Trump D
Urol Oncol; 2016 May; 34(5):247. PubMed ID: 25907623
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Rosenbaum E; Kovel S; Pili R; Sinibaldi V; Carducci MA; Hammers H; Eisenberger MA; Sella A
Oncologist; 2012; 17(12):1508-14. PubMed ID: 22971522
[TBL] [Abstract][Full Text] [Related]
6. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
7. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
8. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Teply BA; Luber B; Denmeade SR; Antonarakis ES
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):72-8. PubMed ID: 26857146
[TBL] [Abstract][Full Text] [Related]
9. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Qu YY; Dai B; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Ma CG; Yang WY
Asian J Androl; 2013 Jan; 15(1):110-5. PubMed ID: 23147466
[TBL] [Abstract][Full Text] [Related]
11. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia.
Choi SY; Ryu J; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Urol Oncol; 2018 Sep; 36(9):401.e11-401.e18. PubMed ID: 30274641
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
14. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration-resistance prostate cancer patients treated with docetaxel.
Shi X; Pei X; Fan J; Liu T; Zhang D; Yang T; Wu K; He D; Li L
Andrologia; 2021 May; 53(4):e13916. PubMed ID: 33591598
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
16. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
17. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
[TBL] [Abstract][Full Text] [Related]
18. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
Yang Z; Ni Y; Zhao D; Zhang Y; Wang J; Jiang L; Chen D; Wu Z; Wang Y; He L; Shi Y; Zhou F; Zeng H; Li Y
BMC Cancer; 2021 Aug; 21(1):919. PubMed ID: 34388965
[TBL] [Abstract][Full Text] [Related]
20. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
Sartor O; Nakabayashi M; Taplin ME; Ross RW; Kantoff PW; Balk SP; Oh WK
Clin Genitourin Cancer; 2009 Oct; 7(3):E90-2. PubMed ID: 19815488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
